Alon Rainish

Alon Rainish

Auto-generated profile, based on publicly available information

Alon Rainish

The Institute of Biochemistry 229 Herzl Street

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
PDF file
NDNitsan Dallal
Nitsan Dallal
GPGil Daniel Paz
Gil Daniel Paz
NNNoga Nir-Marom
Noga Nir-Marom
YKYael Keselman
Yael Keselman
SEShir Eyal
Shir Eyal
MNMasha Y Niv
Masha Y Niv
Bitter taste receptors (TAS2Rs) are G protein-coupled receptors expressed in both gustatory and extraoral tissues and activated by a broad range of compounds. TAS2R14 is among the most promiscuous members of this family, responding to many structurally diverse ligands. Cryo-electron microscopy structures of TAS2R14 have revealed agonists binding in an intracellular pocket, raising the question of the main sites of interaction for known TAS2R14 antagonists. To address this, we examined the effects of mutations at residues located in the extracellular and intracellular regions on receptor inhibition by three antagonist compounds: LF1, LF22 and probenecid. Mutations in the extracellular region reduced the inhibitory effect of LF22, whereas all three compounds showed reduced inhibition in the intracellular mutants. Computational co-folding of these ligands with TAS2R14 supported these observations, indicating that LF22 interacts with both top and bottom binding sites, whereas LF1 and probenecid engage predominantly the intracellular site adjacent to the G protein interface. Interestingly, LF1 is more potent for TAS2R16 than its known inhibitor probenecid. These findings reveal distinct inhibitory mechanisms among TAS2R antagonists and provide new insights into designing inhibitors of bitter taste.

22 January 2025 in Chemical Senses
Verified
Journal Article
Closed access
RNRena Numabe
Rena Numabe
ARAlon Rainish
Alon Rainish
MNMasha Y Niv
Masha Y Niv
HIHIROO IMAI
HIROO IMAI
We investigated the effects of coding single-nucleotide polymorphisms (SNPs) in bitter taste receptors TAS2R43 and TAS2R46 on their predicted structural stability, cellular functions, and human threshold for bitterness of caffeine. We found differences in the cell surface expression and reaction to caffeine among the haplotypes of TAS2R43 and -46 protein. Ancestral haplotypes of the proteins showed higher response to caffeine than derived haplotypes both for TAS2R43 and -46, which were also predicted to be less structurally stable and showed lower expression at the cell surface membrane. There was a significant difference in human bitter perception of caffeine between people with different TAS2R43 genotypes. Considering the functional differences based on their genotypes and the distribution of the haplotypes in the regions, these SNPs in TAS2R43 may relate to the sensitivity to several bitter compounds, which correlated with human evolution spread from Africa.

3 September 2026 in Journal of Chemical Information and Modeling
Verified
Journal Article
Open access
ARAlon Rainish
Alon Rainish
LSLiel Sapir
Liel Sapir
MNMasha Y Niv
Masha Y Niv
Taste perception strongly influences food choice, drug compliance, and dietary behavior. Bitter taste receptors belong to a subfamily of Family A GPCRs, while having unique features and deviations from conserved motifs. Recent cryo-EM structures revealed that the human bitter taste receptor TAS2R14 contains not only the canonical extracellular binding site, but also a novel intracellular site, raising questions about their interplay. Here, we performed all-atom molecular dynamics simulations of TAS2R14 in an explicit membrane to probe different receptor states: both cholesterol (extracellular) and aristolochic acid (intracellular) bound, only cholesterol bound, only aristolochic acid bound, and the apo receptor, with and without the G protein. Ligand occupancy at either site reshaped the volume, hydration, and conformational plasticity of both pockets and modulated the relative proximity of transmembrane helices 3 and 6. In simulations lacking the intracellular agonist but containing cholesterol, we observed intracellular entry of chloride ions and their long-lived interaction with the TAS2R-conserved R55 (BW position 2.50), revealing a charge-inverted interaction relative to the D2.50-sodium interaction described in many class A GPCRs. Apo simulations without G protein showed shorter-lived chloride visits to the same region. Together, these findings point to the intracellular pocket as a promising target for future mechanistic and ligand-design studies on bitter taste GPCRs.

22 June 2026 in bioRxiv
Verified
Preprint
Open access
SEShir Eyal
Shir Eyal
NDNitsan Dallal
Nitsan Dallal
ARAlon Rainish
Alon Rainish
EZEvgenii Ziaikin
Evgenii Ziaikin
EMEinav Malach
Einav Malach
MNMasha Y Niv
Masha Y Niv
Bitter taste receptors (TAS2Rs) are G- protein coupled receptors that detect chemically diverse compounds, including many clinically used drugs. TAS2R14 is expressed in many extraoral tissues and is activated by hundreds of ligands, including pharmaceutical drugs. Recent cryo-EM structures revealed a previously unrecognized intracellular binding pocket in TAS2R14, raising new questions regarding ligand binding modes. Here, we investigated the activation of TAS2R14 by Tamoxifen, Carbimazole, and Lidocaine using cell-based assays measuring proximal G-protein recruitment (BRET2) and downstream signaling (IP-One). Tamoxifen and Carbimazole activated TAS2R14 with EC50 values in the low micromolar range, whereas Lidocaine required substantially higher concentrations. Targeted receptor mutations were used to evaluate the contribution of extracellular and intracellular binding regions to agonist activity. Carbimazole and Lidocaine showed greater dependence on the intracellular and extracellular positions, respectively, while Tamoxifen displayed assay-dependent, but overall modest sensitivity to the tested mutations. Thus, although existing drugs can activate TAS2R14 through distinct binding modes, TAS2R14-directed repurposing will depend on whether effective local receptor concentrations can be achieved through appropriate delivery strategies.